By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on IHE's concentration risk, with its heavy exposure to Eli Lilly and JNJ, particularly regarding GLP-1 drugs. They argue that IHE's 1-year outperformance is not sustainable and may reverse due to regulatory scrutiny, competition, and patent cliffs. Diversification in global healthcare (IXJ) is seen as a safer bet.
Risk: Concentration risk in IHE, particularly its heavy exposure to Eli Lilly and JNJ's GLP-1 drugs, which could face generic competition by 2029-2031.
Opportunity: Diversification in global healthcare offered by IXJ, spreading risk across biotechs, devices, and international players.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
iShares U.S. Pharmaceuticals ETF provides concentrated exposure domestic drug manufacturers while iShares Global Healthcare ETF holds more than 100 companies across the global healthcare sector.
iShares U.S. Pharmaceuticals ETF has delivered a significantly higher 1-year total return compared to iShares Global Healthcare ETF.
Both funds are managed by iShares and carry similar expense ratios with iShares U.S. Pharmaceuticals ETF offering a slightly higher trailing-12-month dividend yield.
iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers concentrated exposure to domestic drugmakers, while iShares Global Healthcare ETF (NYSEMKT:IXJ) provides a broader, international footprint across the wider healthcare sector.
While IHE narrows its focus to companies specifically engaged in the research, development, and production of pharmaceuticals in the U.S., IXJ casts a wider net across various healthcare subsectors on a global scale. This comparison evaluates how these different scopes impact costs, risk, and total performance.
| Metric | IHE | IXJ | |---|---|---| | Issuer | iShares | iShares | | Expense ratio | 0.38% | 0.40% | | 1-yr return (as of May 20, 2026) | 39.70% | 10.00% | | Dividend yield | 1.70% | 1.50% | | Beta | 0.49 | 0.58 | | AUM | $883.6 million | $3.6 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Investors pay nearly identical management fees for these funds, with the 0.40% expense ratio of the iShares global fund sitting just 0.02 percentage points above its pharmaceutical counterpart. The iShares pharmaceutical fund offers a slightly higher distribution yield of 1.70%.
| Metric | IHE | IXJ | |---|---|---| | Max drawdown (5 yr) | (16.00%) | (18.10%) | | Growth of $1,000 over 5 years (total return) | $1,570 | $1,220 |
The iShares global fund offers a diversified approach to the healthcare space, containing 114 holdings. Its portfolio includes global companies in the pharmaceuticals, biotechnology, and healthcare equipment industries. Its largest positions include Eli Lilly (NYSE:LLY) at 10.50%, Johnson & Johnson (NYSE:JNJ) at 7.19%, and AbbVie (NYSE:ABBV) at 4.88%. This fund was launched in 2001, has a trailing-12-month dividend of $1.36 per share, and maintains assets under management (AUM) of $3.6 billion.
In contrast, the iShares pharmaceutical fund targets a much narrower segment of the market with its 55 holdings. Its top holdings include Eli Lilly (NYSE:LLY) at 22.91%, Johnson & Johnson (NYSE:JNJ) at 21.22%, and Viatris (NASDAQ:VTRS) at 5.24%. Because it focuses exclusively on domestic drugmakers, it has high concentration in its top two holdings. Launched in 2006, the fund has paid $1.49 per share over the trailing 12 months and manages approximately $883.6 million in AUM.
For more guidance on ETF investing, check out the full guide at this link.
There’s been a significant performance gap between these two ETFs over the past year, and it comes down largely to one reason: GLP-1s.
Eli Lilly, whose weight-loss and diabetes drugs Mounjaro and Zepbound became two of the fastest-growing pharmaceutical products in history, sits as a top holding in IHE. As GLP-1 drugs reshaped the pharmaceutical landscape in 2025, concentrated domestic pharma funds captured that wave directly. IXJ's broader global mandate spread exposure across biotechnology, medical devices, and international healthcare companies, diluting the GLP-1 effect considerably.
For long-term investors, the lesson cuts both ways. Concentration in IHE delivered extraordinary recent returns but creates real vulnerability if the GLP-1 tailwind slows or drug pricing pressure intensifies. IXJ's broader approach smooths those peaks and valleys across the full healthcare ecosystem. Both funds charge nearly identical fees, making the choice purely about how much concentration an investor wants in a single corner of healthcare.
Before you buy stock in iShares Trust - iShares Global Healthcare ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Trust - iShares Global Healthcare ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,852! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,317,207!
Now, it’s worth noting Stock Advisor’s total average return is 984% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 27, 2026. *
Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"IHE's extreme top-two concentration creates reversal risk that the recent GLP-1 outperformance does not justify versus IXJ."
The article correctly ties IHE's 39.7% 1-year return to its 22.9% Eli Lilly weighting versus IXJ's 10.5%, but glosses over how IHE's 55-stock domestic focus creates 44% top-two concentration that IXJ's 114 global holdings avoid. With identical 0.38-0.40% fees, the performance gap reflects a single tailwind rather than structural superiority. Max drawdowns of 16% versus 18.1% over five years also mask that IHE's lower beta of 0.49 stems from narrow exposure, not resilience. Any slowdown in GLP-1 uptake or renewed U.S. pricing pressure would hit IHE harder than IXJ's device and international diversification.
Lilly's expanding indications and multi-year GLP-1 runway could keep driving IHE returns while IXJ remains diluted by slower-growing ex-U.S. and non-pharma holdings.
"IHE's outperformance reflects a single-stock bet on LLY's GLP-1 cycle that is already heavily priced in, not superior pharma exposure, and the fund's low beta masks dangerous concentration risk."
The article frames IHE's 39.7% return as GLP-1 vindication, but that's survivorship bias masquerading as analysis. IHE is 44% LLY+JNJ—a duopoly bet, not pharma exposure. The real risk: GLP-1 adoption is already priced in. Mounjaro/Zepbound face generic competition by 2029-2031, and LLY's forward multiple has expanded to ~60x on GLP-1 hype. IXJ's 'broader approach' isn't weakness—it's optionality. Medical devices, diagnostics, and international plays offer genuine diversification. The article ignores that IHE's 0.49 beta is artificially low due to LLY/JNJ's defensive profiles, masking concentration risk.
If GLP-1 adoption accelerates faster than consensus expects and LLY maintains pricing power longer than generics timelines suggest, IHE's concentration becomes a feature, not a bug—and the 39.7% gap could widen further.
"IHE is currently functioning as a high-beta momentum vehicle rather than a diversified healthcare investment, making it dangerously exposed to a potential correction in the GLP-1 narrative."
The performance gap between IHE and IXJ isn't just about GLP-1s; it’s a masterclass in concentration risk. IHE’s ~44% exposure to just two stocks—Eli Lilly and JNJ—essentially turns it into a leveraged bet on a single drug class. While the 39.7% return looks attractive, investors are essentially ignoring the regulatory and patent-cliff risks inherent in such a narrow basket. Conversely, IXJ offers a defensive hedge through global diversification, including medical devices and services that aren't tied to the volatility of obesity drug pricing. IHE is a momentum trade masquerading as a sector play, and its current valuation likely leaves zero margin for error regarding future GLP-1 pricing power.
If the GLP-1 market expands into cardiovascular and neurodegenerative indications as projected, IHE's extreme concentration could continue to outperform as the market rewards 'pure-play' winners over diversified laggards.
"Long-run outperformance hinges on more than a GLP-1 wave; diversification across healthcare ecosystems is more resilient than a concentrated bet on one therapeutic trend."
The article frames IHE’s 1-year outperformance as a direct result of GLP-1 tailwinds, implying a durable advantage from concentration. Yet the strength hinges on a narrow theme (GLP-1s) that could fade or reverse amid pricing pressures, regulatory scrutiny, and competition (e.g., other GLP-1 developers). A global healthcare sleeve (IXJ) spreads risk across biotechs, devices, and international players, potentially reducing drawdowns if GLP-1 demand slows. The window shown (as of May 20, 2026) may mask mean reversion and cycle risks; long-run returns depend more on pipelines and pricing cycles than on a single product class.
The GLP-1 tailwind could persist longer than expected, and IHE’s heavy weights in Lilly/J&J may continue to drive performance, making IXJ look unattractive by comparison.
"IXJ's international diversification embeds unexamined currency risk that favors IHE in strong-dollar periods."
IXJ's global holdings introduce FX volatility that IHE avoids entirely through its U.S.-only mandate. A 10% yen or euro swing directly hits IXJ returns without any offsetting GLP-1 exposure, an effect the beta and drawdown numbers cited so far do not isolate. In a persistent strong-dollar regime this tilts the risk comparison toward IHE more than the diversification narrative suggests, regardless of concentration levels.
"FX drag on IXJ is real but secondary to IHE's unpriced patent-cliff earnings cliff in 2029-2031."
Grok's FX volatility point is real but overstated. IXJ's 114 holdings include ~40% U.S. exposure, so currency drag isn't symmetric to IHE's full domestic mandate. More critical: nobody has quantified IHE's earnings sensitivity to GLP-1 price erosion post-2029. If LLY's GLP-1 revenue drops 30-40% when generics arrive, IHE's 60x forward multiple implodes faster than IXJ's diversified 18x. That's the actual tail risk hiding in the concentration debate.
"Lilly's broader pipeline in neurodegeneration and metabolic disease provides a structural hedge that mitigates the 2029 GLP-1 patent cliff risk."
Claude, your focus on the 2029 patent cliff is valid, but you are ignoring the 'platform' effect. Lilly isn't just a GLP-1 play; they are aggressively pivoting into Alzheimer's (donanemab) and metabolic syndrome, which provides a revenue bridge beyond the obesity peak. IHE isn't just betting on a drug; it is betting on Lilly's R&D execution. If the pipeline matures, the 60x multiple isn't an 'implosion' risk—it is a valuation floor for a dominant biopharma leader.
"FX risk is not immunized by the 'U.S.-only' label; both IHE and IXJ carry currency exposure, so the domestic concentration argument overstates IHE's advantage."
Grok, 'U.S.-only' for IHE isn't FX-free. LLY and JNJ are highly multinational; their earnings face currency translation and hedging risks, so IHE isn't immune to FX. IXJ's currency exposure isn't the only risk either. If dollar moves persist, both ETFs can suffer, which means the supposed domestic concentration advantage is overstated. The real signal is how much FX risk each manager actually hedges, not the domicile label alone.
The panel consensus is bearish on IHE's concentration risk, with its heavy exposure to Eli Lilly and JNJ, particularly regarding GLP-1 drugs. They argue that IHE's 1-year outperformance is not sustainable and may reverse due to regulatory scrutiny, competition, and patent cliffs. Diversification in global healthcare (IXJ) is seen as a safer bet.
Diversification in global healthcare offered by IXJ, spreading risk across biotechs, devices, and international players.
Concentration risk in IHE, particularly its heavy exposure to Eli Lilly and JNJ's GLP-1 drugs, which could face generic competition by 2029-2031.